Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Allarity Therapeutics (ALLR) Income from Continuing Operations (2024 - 2025)

Allarity Therapeutics' Income from Continuing Operations history spans 2 years, with the latest figure at 2296000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 74.27% year-over-year to 2296000.0; the TTM value through Dec 2025 reached 5530000.0, up 32.06%, while the annual FY2025 figure was 5562000.0, 31.66% up from the prior year.
  • Income from Continuing Operations reached 2296000.0 in Q4 2025 per ALLR's latest filing, up from 2806000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 8923000.0 in Q4 2024 to a low of 11590000.0 in Q3 2024.